Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 22 · above the Ichimoku cloud · RSI 63 · MACD above its signal
| 5.40 | 52-week high | +33.66% |
| 4.09 | Previous month high | +1.24% |
| 4.08 | R3 (classic) | +0.99% |
| 4.06 | R2 (classic) | +0.50% |
| 4.05 | R1 (classic) | +0.25% |
| 4.04 | Price now | |
| 4.04 | Previous day high | −0.00% |
| 4.04 | Previous week high | −0.00% |
| 4.03 | Pivot | −0.25% |
| 4.02 | S1 (classic) | −0.50% |
| 4.01 | Previous day low | −0.74% |
| 4.00 | S2 (classic) | −0.99% |
| 3.99 | S3 (classic) | −1.24% |
| 3.89 | Previous week low | −3.71% |
| 2.73 | Previous month low | −32.43% |
| 1.48 | 52-week low | −63.37% |
None of the 29 investors followed here reported a position in NORD in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NORD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NORD.
TimeframesUp on the hourly and daily, down on the monthly, mixed on the weekly.
over a rising 21 EMA, 21 over 50
over a rising 21 EMA, 21 over 50
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.0 | -12.0 | -17.9 | 21.5 | 1.5 | -39.9 | -6.6 | 80.9 | -13.8 | 15.1 | −19.2% | ||
| 2025 | 5.4 | -52.6 | 5.6 | 5.3 | -30.0 | -45.7 | 0.0 | 0.0 | 150.0 | 5.3 | -4.0 | 4.2 | −44.4% |
| 2024 | -21.0 | -8.2 | 35.6 | 8.2 | 21.2 | 0.0 | -1.2 | -35.4 | 13.7 | -5.2 | -48.2 | 215.8 | +45.2% |
| 2023 | -44.4 | 0.0 | 54.5 | -4.7 | -7.4 | -6.7 | 5.7 | -2.7 | -2.8 | -4.3 | -3.0 | -4.6 | −37.4% |
| 2022 | 0.0 | 0.0 | 22.0 | 23.0 | 13.3 | -26.5 | 12.0 | -10.7 | -8.8 | 0.0 | -1.8 | -11.6 | −1.0% |
| 2021 | -33.3 | 50.0 | 0.0 | -33.3 | 0.0 | 0.0 | 50.0 | -33.3 | 100.0 | -25.0 | -33.3 | 0.0 | −33.3% |
| 2020 | 5.9 | -5.6 | -17.6 | -78.6 | 0.0 | 0.0 | -33.3 | 0.0 | 0.0 | 100.0 | -25.0 | 0.0 | −82.4% |
| 2019 | 20.0 | 50.0 | 0.0 | 44.4 | -30.8 | 0.0 | -11.1 | 62.5 | 38.5 | -16.7 | 0.0 | 13.3 | +240.0% |
| 2018 | 0.0 | 0.0 | -20.0 | -25.0 | 66.7 | 60.0 | -37.5 | 40.0 | 14.3 | -12.5 | 0.0 | -28.6 | 0.0% |
| 2017 | 40.0 | -14.3 | -33.3 | 0.0 | 25.0 | 0.0 | 80.0 | -11.1 | 0.0 | 0.0 | -25.0 | -16.7 | 0.0% |
| 2016 | 0.0 | -35.5 | -10.0 | -22.2 | 0.0 | -42.9 | 0.0 | -12.5 | 14.3 | -12.5 | 0.0 | -28.6 | −83.9% |
| 2015 | 50.0 | 0.0 | 33.3 | 0.0 | -25.0 | 33.3 | -25.0 | 366.7 | -14.3 | 25.0 | 0.0 | 106.7 | +1450.0% |
| 2014 | 20.0 | -16.7 | 0.0 | 20.0 | 16.7 | -14.3 | 33.3 | -25.0 | -33.3 | 25.0 | -60.0 | 0.0 | −60.0% |
| 2013 | 0.0 | 100.0 | -16.7 | 60.0 | 0.0 | 50.0 | -33.3 | -25.0 | 16.7 | -14.3 | -16.7 | 0.0 | +66.7% |
| 2012 | -33.3 | 150.0 | -40.0 | 0.0 | -33.3 | 0.0 | 0.0 | -50.0 | 600.0 | -42.9 | -50.0 | 50.0 | +0.0% |
| 2011 | 0.0 | -27.3 | -25.0 | 100.0 | -25.0 | 0.0 | 11.1 | -30.0 | -14.3 | -50.0 | 0.0 | 0.0 | −72.7% |
| 2010 | 10.7 | 3.2 | -6.3 | 26.7 | -21.1 | -3.3 | -17.2 | 12.5 | 3.7 | -17.9 | -34.8 | -26.7 | −60.7% |
| 2009 | 28.0 | -46.9 | 5.9 | 44.4 | 19.2 | 16.1 | -11.1 | 0.0 | -6.3 | -10.0 | -11.1 | 16.7 | +12.0% |
| 2008 | 47.1 | -32.0 | -20.6 | 11.1 | -15.0 | 41.2 | -26.4 | -1.9 | -15.4 | -29.5 | -9.7 | -10.7 | −63.2% |
| 2007 | -3.6 | -18.1 | 1.3 | -3.8 | -13.3 | 2.3 | -0.8 | -6.8 | 13.8 | -10.0 | -27.0 | -26.1 | −65.1% |
No analyst coverage for this instrument.
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.